Randomised, Multicenter Phase III Clinical Study Of Nanoplatin Plus Pemetrexed Versus Cisplatin Plus Pemetrexed As First Line Treatment In Inoperable (Stage III/IV) Non-Small Cell Lung Cancer Of Non-Squamous Type

Trial Profile

Randomised, Multicenter Phase III Clinical Study Of Nanoplatin Plus Pemetrexed Versus Cisplatin Plus Pemetrexed As First Line Treatment In Inoperable (Stage III/IV) Non-Small Cell Lung Cancer Of Non-Squamous Type

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs Cisplatin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Regulon
  • Most Recent Events

    • 05 Oct 2016 Status changed from planning to recruiting.
    • 12 Jun 2012 Planned number of patients changed to 880, according to a Regulon media release.
    • 12 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top